Diagnostic utility of lipocalin 2 and metalloproteinase 9 levels in early-stage endometrial cancer.

IF 2.2 4区医学 Q3 ONCOLOGY

Cancer Biomarkers Pub Date : 2024-12-01 DOI:10.1177/18758592241290951

Songül Ünüvar, Rauf Melekoğlu, Hande Yüce, Nesibe Zeyveli Çelik, Ezgi Bulut Okumuş, Serhat Toprak, Kevser Tanbek, Şeyma Yaşar, Ayşegül Doğan, Neşe Başak Türkmen, Ercan Yılmaz, Süleyman Sandal

{"title":"Diagnostic utility of lipocalin 2 and metalloproteinase 9 levels in early-stage endometrial cancer.","authors":"Songül Ünüvar, Rauf Melekoğlu, Hande Yüce, Nesibe Zeyveli Çelik, Ezgi Bulut Okumuş, Serhat Toprak, Kevser Tanbek, Şeyma Yaşar, Ayşegül Doğan, Neşe Başak Türkmen, Ercan Yılmaz, Süleyman Sandal","doi":"10.1177/18758592241290951","DOIUrl":null,"url":null,"abstract":"Background: Endometrial cancer (EC) is the fourth most common gynecologic malignancy among women. Histopathologic examination is considered gold-standard for diagnosis of EC. However, these examinations sometimes not be useful in distinguishing early stage types of EC.Objectives: The current study aimed to investigate the clinicopathological significance of Lipocalin-2 (LCN2), matrix metalloproteinase-9 (MMP9), and ferritin in tumor progression.Methods: A total of 98 patients (55 women newly diagnosed with early-stage endometrial cancer [study group] and 43 women with benign endometrial pathologies [control group]) were enrolled.Results: There was a significant difference between diagnosis (p < 0.001), surgical procedure (p < 0.001), pathology (p = 0.002), stage (p < 0.001), lymphovascular invasion (LVI) (p = 0.002), myometrial invasion (p < 0.001), and staining intensity (p < 0.001), MMP9 (p = 0.023), LCN2 (p < 0.001), glucocorticoid (GC) (p = 0.048), tumor necrosis factor-alpha (TNF-α) (p = 0.044), menopause duration (p = 0.001), body weight (p < 0.001), and body mass index (BMI) (p < 0.001) were found to be higher, and ferritin levels (p = 0.047) were lower in the endometrial adenocarcinoma group compared to the benign endometrial pathologies.Conclusion: LCN2, MMP9, and ferritin are practical markers in early cases of endometrial cancer. Serum LCN2 and MMP9 levels may be good clinical tools for the auxiliary diagnosis of early-stage endometrial cancer. Ferritin was also significantly sensitive. Therefore, detecting these markers together may be more beneficial for cancer diagnosis.","PeriodicalId":56320,"journal":{"name":"Cancer Biomarkers","volume":"41 3","pages":"18758592241290951"},"PeriodicalIF":2.2000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Biomarkers","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/18758592241290951","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Endometrial cancer (EC) is the fourth most common gynecologic malignancy among women. Histopathologic examination is considered gold-standard for diagnosis of EC. However, these examinations sometimes not be useful in distinguishing early stage types of EC.

Objectives: The current study aimed to investigate the clinicopathological significance of Lipocalin-2 (LCN2), matrix metalloproteinase-9 (MMP9), and ferritin in tumor progression.

Methods: A total of 98 patients (55 women newly diagnosed with early-stage endometrial cancer [study group] and 43 women with benign endometrial pathologies [control group]) were enrolled.

Results: There was a significant difference between diagnosis (p < 0.001), surgical procedure (p < 0.001), pathology (p = 0.002), stage (p < 0.001), lymphovascular invasion (LVI) (p = 0.002), myometrial invasion (p < 0.001), and staining intensity (p < 0.001), MMP9 (p = 0.023), LCN2 (p < 0.001), glucocorticoid (GC) (p = 0.048), tumor necrosis factor-alpha (TNF-α) (p = 0.044), menopause duration (p = 0.001), body weight (p < 0.001), and body mass index (BMI) (p < 0.001) were found to be higher, and ferritin levels (p = 0.047) were lower in the endometrial adenocarcinoma group compared to the benign endometrial pathologies.

Conclusion: LCN2, MMP9, and ferritin are practical markers in early cases of endometrial cancer. Serum LCN2 and MMP9 levels may be good clinical tools for the auxiliary diagnosis of early-stage endometrial cancer. Ferritin was also significantly sensitive. Therefore, detecting these markers together may be more beneficial for cancer diagnosis.

查看原文本刊更多论文

脂钙素2和金属蛋白酶9在早期子宫内膜癌中的诊断价值。

背景：子宫内膜癌（EC）是女性第四大常见妇科恶性肿瘤。组织病理学检查被认为是诊断EC的金标准。然而，这些检查有时不能用于区分早期类型的EC。目的：本研究旨在探讨脂钙素-2 （LCN2）、基质金属蛋白酶-9 （MMP9）和铁蛋白在肿瘤进展中的临床病理意义。方法：共纳入98例患者，其中55例为新诊断的早期子宫内膜癌（研究组），43例为子宫内膜良性病变（对照组）。结论：LCN2、MMP9、铁蛋白是子宫内膜癌早期诊断的实用标志物。血清LCN2和MMP9水平可能是早期子宫内膜癌辅助诊断的良好临床工具。铁蛋白也非常敏感。因此，同时检测这些标记物可能对癌症诊断更有益。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Biomarkers ONCOLOGY-

CiteScore

5.20

自引率

3.20%

发文量

195

审稿时长

3 months

期刊介绍： Concentrating on molecular biomarkers in cancer research, Cancer Biomarkers publishes original research findings (and reviews solicited by the editor) on the subject of the identification of markers associated with the disease processes whether or not they are an integral part of the pathological lesion. The disease markers may include, but are not limited to, genomic, epigenomic, proteomics, cellular and morphologic, and genetic factors predisposing to the disease or indicating the occurrence of the disease. Manuscripts on these factors or biomarkers, either in altered forms, abnormal concentrations or with abnormal tissue distribution leading to disease causation will be accepted.